To determine the prevalence of HIV, HBV, and HCV in patients seeking treatment for substance use and to raise awareness among those unaware of their infections.
Key Findings:
Overall HBsAg, anti-HBs, anti-HCV, and anti-HIV positivity rates were 2.2%, 33.2%, 0.8%, and 0.6%, respectively.
In the PWID group, seropositivity rates were significantly higher: 25% for HBsAg, 24.4% for anti-HCV, and 10.7% for anti-HIV.
Men showed higher positivity rates for HBsAg and anti-HBs compared to women.
Interpretation:
The prevalence of HBV and HCV among drug users in Turkey is comparable to the general population, but awareness and treatment are crucial to prevent severe health outcomes.
Limitations:
Retrospective nature may limit the comprehensiveness of data.
Potential underreporting of substance use and infections.
Conclusion:
Raising awareness and ensuring treatment for HIV, HBV, and HCV among drug users is essential for public health and preventing disease transmission.
